AstraZeneca Stock Soars 7%, Adding $20 Billion, As Cancer Drugs Lift Quarterly Profit

The drugmaker reconfirmed its 2026 outlook and launched a savings program as oncology offset generic competition for Farxiga.

Share
AstraZeneca Stock Soars 7%, Adding $20 Billion, As Cancer Drugs Lift Quarterly Profit

AstraZeneca shares climbed 7.36% to $187.23 in Friday trading, as of 9:59 a.m. ET, adding about $20 billion in market value after the drugmaker reported third-quarter earnings driven by cancer drugs. It also reconfirmed its 2026 guidance and unveiled a savings program that will reinvest $1.5 billion a year in its drug pipeline.

Cancer sales offset a Farxiga drop

Core earnings per share came in at $2.79, up 17%, on third-quarter revenue of $16.2 billion, up 7% from a year earlier, the company reported.

Oncology, the largest business at 48% of revenue, saw sales rise 17% to $7.8 billion. Farxiga, the diabetes and kidney drug, fell 25% to $1.6 billion after cheaper US generic versions launched.

AstraZeneca, based in Cambridge, UK, develops and sells prescription medicines and vaccines, spanning cancer, cardiovascular, renal and metabolic disease, respiratory and immunology, and rare disease. Imfinzi, Tagrisso and Enhertu are among its marketed cancer drugs.

A $1.5 billion savings plan

The company launched a program to generate $1.5 billion in annual savings. Restructuring will cost up to $2 billion in one-off charges and is due to be largely complete by the end of 2029.

A stock that had lagged the market

The stock was on pace for its biggest one-day gain since Oct. 1, 2025, when it rose 10.0%. Before Friday, shares were down about 5% year to date as of Thursday's close, while the S&P 500 was up about 13% over the same span.

Management has said it remains on track for its 2030 target of $80 billion in annual revenue, up from almost $59 billion in 2025, with half of that expected from the US.

The $80 billion revenue target for 2030 is the benchmark management says it is still on track to meet.

Sources

More on AstraZeneca

All AstraZeneca (AZN) coverage →